Health Related Quality of Life (HRQL) and Health Utilities (HU) of Patients With Chronic Hepatitis C (CH-C) Treated With an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF)

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

    Plenary Session 2: Liver
    Tuesday, October 21
    8:30 am – 10:00 am

    MODERATORS: Kris V. Kowdley, MD, FACG
    Paul Y. Kwo, MD, FACG

    Oral 32: Health Related Quality of Life (HRQL) and Health Utilities (HU) of Patients With Chronic Hepatitis C (CH-C) Treated With an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF)

    Zobair Younossi, MD, MPH, FACG, Maria Stepanova, PhD, Patrick Marcellin, MD, PhD, Nezam Afdhal, MD, Kris V. Kowdley, MD, FACG, Stefan Zeuzem, MD, Linda Henry, PhD, Sharon Hunt, MBA, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA; CLDQ LLC, Washington, DC, Viral Hepatitis Research Unit in Hospital Beaujon, Clichy, France, Beth Israel Deaconess Medical Center, Boston, MA, Digestive Diseases Institute, Digestive Diseases Institute, Virginia Mason Clinic, Seattle, WA, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA

    Read abstract


     

    Embargo Policy

    All research presented at the ACG Annual Scientific Meeting is strictly embargoed until 8:00 a.m. on the first day of the Annual Meeting. For 2014, this is Monday, October 20 at 8:00 a.m. EDT.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks